Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s ...

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth quarter year over year, despite ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, a move investors said eases some concerns ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...